Key result
Percutaneous pulmonary valve implantation is a significant advance for congenital heart disease, with prestenting lowering stent fractures, though coronary compression remains a major hazard.
Answers are grounded in this paper and cite their sources.
Percutaneous pulmonary valve implantation is a major advance in treating congenital heart disease, but carries risks of coronary compression and conduit rupture.
Percutaneous pulmonary valve implantation is one of the most significant advances in catheter interventional treatment of patients with congenital heart disease within the last 10 years. The lifetime of biological conduits in the right ventricular outflow tract can be expanded and, hence, patients may have fewer open heart surgeries during their lifetime. Careful patient selection is mandatory. The correct timing of percutaneous pulmonary valve implantation, especially in the presence of prevailing pulmonary regurgitation, is still a matter of debate. Prestenting ensures a good hemodynamic result, lowers the incidence of stent fractures and enables the treatment of patients with a ‘native’ right ventricular outflow tract. Coronary arterial compression and conduit rupture are the major periprocedural hazards. The only fatalities occurred after coronary arterial compression. Further studies are needed to demonstrate the excellent short time results are sustained over time. The intervention should only be ca...
No takes yet. Share an insight, caveat, or question.
Eicken et al. (2012) conducted a review in Congenital heart disease. Percutaneous pulmonary valve implantation was evaluated. Percutaneous pulmonary valve implantation is a significant advance for congenital heart disease, with prestenting lowering stent fractures, though coronary compression remains a major hazard.
Synapse has enriched 10 related papers. Consider them for comparative context: